EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt,Germany in the US and Canada, has announced the appointment of Craig Millian as Senior Vice President, Neurology and Immunology. Mr. Millian most recently served as Senior Vice President, Head of US Fertility and Endocrinology at EMD Serono. In his new role, he will lead the strategic direction of the Company's US Neurology and Immunology franchise.
"Craig is a dynamic leader with a proven track record of success," said Gary Zieziula, President and Managing Director of EMD Serono. "He has been instrumental in expanding our leadership in Fertility and Endocrinology, and he will bring that passion and expertise to the Neurology and Immunology business, furthering our commitment to improving care for people living with multiple sclerosis and other conditions as we advance our pipeline."
Mr. Millian joined EMD Serono in 2010 to lead the Fertility and Endocrinology marketing team. He previously served as Vice President, Commercial at Vertex, where he helped design and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product pipeline. Prior to Vertex, he held commercial leadership roles at Pfizer and Sanofi. Mr. Millian holds an MBA from New York University and a degree in Finance from the University of Pennsylvania.
Drew Young, who previously served as Senior Vice President, Neurology and Immunology for EMD Serono, has recently been appointed to a new position within Merck KGaA, Darmstadt, Germany. He will serve as General Manager and Managing Director, Merck KGaA, Darmstadt, Germany, Biopharma, Australia & New Zealand, effective September 1, 2016. Mr. Young joined EMD Serono in June 2014 and had a positive impact on the company's neurology and immunology performance.